Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy - PubMed (original) (raw)
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy
S F Shariat et al. J Clin Oncol. 2001.
Abstract
Purpose: Elevated local and circulating levels of transforming growth factor beta(1) (TGF-beta(1)) have been associated with prostate cancer invasion and metastasis. We tested the hypothesis that preoperative plasma TGF-beta(1) levels would independently predict cancer stage and prognosis in patients who undergo radical prostatectomy.
Patients and methods: The study group consisted of 120 consecutive patients who underwent radical prostatectomy for clinically localized prostate cancer (median follow-up, 53.8 months). Preoperative plasma levels of TGF-beta(1) were measured and correlated with pathologic parameters and clinical outcomes. TGF-beta(1) levels also were measured in 44 healthy men without cancer, in 19 men with prostate cancer metastatic to regional lymph nodes, and in 10 men with prostate cancer metastatic to bone.
Results: Plasma TGF-beta(1) levels in patients with lymph node metastases (14.2 +/- 2.6 ng/mL) and bone metastases (15.5 +/- 2.4 ng/mL) were higher than those in radical prostatectomy patients (5.2 +/- 1.3 ng/mL) and healthy subjects (4.5 +/- 1.2 ng/mL) (P <.001). In a preoperative analysis, preoperative plasma TGF-beta(1) level and biopsy Gleason sum both were predictors of organ-confined disease (P =.006 and P =.006, respectively) and PSA progression (P <.001 and P =.021, respectively). In a postoperative multivariate analysis, preoperative plasma TGF-beta(1) level, pathologic Gleason sum, and surgical margin status were predictors of PSA progression (P =.020,P =.020, and P =.022, respectively). In patients who progressed, preoperative plasma TGF-beta(1) levels were higher in those with presumed distant compared with local-only failure (P =.019).
Conclusion: Plasma TGF-beta(1) levels are markedly elevated in men with prostate cancer metastatic to regional lymph nodes and bone. In men without clinical or pathologic evidence of metastases, the preoperative plasma TGF-beta(1) level is a strong predictor of biochemical progression after surgery, presumably because of an association with occult metastatic disease present at the time of radical prostatectomy.
Similar articles
- Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM. Shariat SF, et al. J Clin Oncol. 2002 Feb 1;20(3):833-41. doi: 10.1200/JCO.2002.20.3.833. J Clin Oncol. 2002. PMID: 11821468 - Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
Shariat SF, Menesses-Diaz A, Kim IY, Muramoto M, Wheeler TM, Slawin KM. Shariat SF, et al. Urology. 2004 Jun;63(6):1191-7. doi: 10.1016/j.urology.2003.12.015. Urology. 2004. PMID: 15183988 - Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW. Moul JW. Eur Urol. 1999;35(5-6):399-407. doi: 10.1159/000019916. Eur Urol. 1999. PMID: 10325496 Review. - Molecular markers in prostate cancer: the role in preoperative staging.
Moul JW, Merseburger AS, Srivastava S. Moul JW, et al. Clin Prostate Cancer. 2002 Jun;1(1):42-50. doi: 10.3816/cgc.2002.n.006. Clin Prostate Cancer. 2002. PMID: 15046712 Review.
Cited by
- Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells.
Konrad L, Scheiber JA, Völck-Badouin E, Keilani MM, Laible L, Brandt H, Schmidt A, Aumüller G, Hofmann R. Konrad L, et al. BMC Genomics. 2007 Sep 11;8:318. doi: 10.1186/1471-2164-8-318. BMC Genomics. 2007. PMID: 17845732 Free PMC article. - Role of serum and urine transforming growth factor beta 1, matrix metallopeptidase 9, tissue inhibitor of metalloproteinase 2, and nerve growth factor beta levels and serum neutrophil-to-lymphocyte ratio in predicting recurrence and progression risks in patients with primary non-muscle invasive bladder cancer.
Efiloğlu Ö, Başok Bİ, Turan T, Toprak T, Erol B, Çaşkurlu T, Yıldırım A. Efiloğlu Ö, et al. Turk J Urol. 2020 Feb 7;46(3):206-212. doi: 10.5152/tud.2020.19186. Print 2020 May. Turk J Urol. 2020. PMID: 32053096 Free PMC article. - TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.
Ratz L, Laible M, Kacprzyk LA, Wittig-Blaich SM, Tolstov Y, Duensing S, Altevogt P, Klauck SM, Sültmann H. Ratz L, et al. Oncotarget. 2017 Apr 11;8(15):25115-25130. doi: 10.18632/oncotarget.15931. Oncotarget. 2017. PMID: 28445989 Free PMC article. - The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
Turner CJ, Edwards CM. Turner CJ, et al. Curr Osteoporos Rep. 2016 Oct;14(5):170-7. doi: 10.1007/s11914-016-0323-2. Curr Osteoporos Rep. 2016. PMID: 27566487 Review. - A list of candidate cancer biomarkers for targeted proteomics.
Polanski M, Anderson NL. Polanski M, et al. Biomark Insights. 2007 Feb 7;1:1-48. Biomark Insights. 2007. PMID: 19690635 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous